Yang Li
Research Subjects
Research Interests
Yang Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hengdi Zhang
PaXini Tech, Shenzhen, China
1 shared publication - Hongmei Wang
Shaanxi University of Chinese Medicine, Xianyang, China
1 shared publication - Li Song
Shanghai Jiao Tong University, Shanghai, China
1 shared publication - Nannan Ning
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Ruibao Ren
International Center for Aging and Cancer, Hainan Medical University, Haikou 571199, China
1 shared publication - Yan Zhao
School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 26 October 2025
- Published by Association for Computing Machinery (ACM)
- p. 54-62
TacCompress: A Benchmark for Multi-Point Tactile Data Compression in Dexterous Hand
- 26 October 2025
- Published by Association for Computing Machinery (ACM)
- p. 54-62
Open AccessTacCompress: A Benchmark for Multi-Point Tactile Data Compression in Dexterous Hand
- Open Access
- 13 December 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-11
A novel microtubule inhibitor promotes tumor ferroptosis by attenuating SLC7A11/GPX4 signaling
MP-HJ-1b is a novel microtubule inhibitor that we designed and reported previously. Ferroptosis is a newly identified type of nonapoptotic cell death induced by ferrous catalysis and lipid peroxidation. Here, transcriptomics, proteomics, and molecular docking analyses were combined to explore the novel effects of MP-HJ-1b on tumors. Both omics analyses suggested that MP-HJ-1b affects ribosomes, and we confirmed that it inhibits the ribosomal component proteins RPL35 and MRPL28. Colchicine was used as an analog, and the results showed that MP-HJ-1b and colchicine increased reactive oxygen species and malondialdehyde levels and decreased reduced glutathione levels, suggesting that they promoted ferroptosis in HeLa cells. Specifically, MP-HJ-1b downregulated SLC7A11 and GPX4 to enhance the classical pathway of ferroptosis, while colchicine upregulated LC3A/B-II and enhanced autophagy. Clinically, the serum concentrations of ferrous ions, reduced glutathione, and Hcy were higher in cervical cancer patients than in healthy individuals. ALT, AST, Cho, HDL-C, and LDL-C levels were decreased in the serum of patients. Our study expands understanding of the way MP-HJ-1b promotes cell death and enriches research on microtubule inhibitors in the ferroptosis field.
- 13 December 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-11
Open AccessA novel microtubule inhibitor promotes tumor ferroptosis by attenuating SLC7A11/GPX4 signaling
MP-HJ-1b is a novel microtubule inhibitor that we designed and reported previously. Ferroptosis is a newly identified type of nonapoptotic cell death induced by ferrous catalysis and lipid peroxidation. Here, transcriptomics, proteomics, and molecular docking analyses were combined to explore the novel effects of MP-HJ-1b on tumors. Both omics analyses suggested that MP-HJ-1b affects ribosomes, and we confirmed that it inhibits the ribosomal component proteins RPL35 and MRPL28. Colchicine was used as an analog, and the results showed that MP-HJ-1b and colchicine increased reactive oxygen species and malondialdehyde levels and decreased reduced glutathione levels, suggesting that they promoted ferroptosis in HeLa cells. Specifically, MP-HJ-1b downregulated SLC7A11 and GPX4 to enhance the classical pathway of ferroptosis, while colchicine upregulated LC3A/B-II and enhanced autophagy. Clinically, the serum concentrations of ferrous ions, reduced glutathione, and Hcy were higher in cervical cancer patients than in healthy individuals. ALT, AST, Cho, HDL-C, and LDL-C levels were decreased in the serum of patients. Our study expands understanding of the way MP-HJ-1b promotes cell death and enriches research on microtubule inhibitors in the ferroptosis field.